20110103
 New Breast Cancer Drug Found Deep In the Sea   By Landers, Peter, The Wall Street Journal,  Jan 4, 2011  Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases. The best-known, Novartis AG's Gleevec, which went on the market in 2001, works by turning off the protein blamed for triggering chronic myeloid leukemia, a cancer of the blood and bone marrow.   
